10-Q: Protalix BioTherapeutics Q1 2026 Financials Show Strong Revenue Growth

Protalix BioTherapeutics reports a significant increase in total revenue for Q1 2026, driven by license and R&D services, alongside a substantial improvement in operating income.

Summary

• Protalix BioTherapeutics reported total revenues of $33.75 million for the three months ended March 31, 2026, a substantial increase from $10.11 million in the same period of 2025.
• This revenue growth was primarily driven by a significant surge in 'Revenues from License and R&D Services', which rose from $0.118 million in Q1 2025 to $26.33 million in Q1 2026.
• Revenues from selling goods decreased by 26% to $7.42 million in Q1 2026 compared to $9.99 million in Q1 2025, attributed to timing shifts in orders from Pfizer and Fiocruz, partially offset by increased sales to Chiesi.
• Cost of revenues decreased by 50% to $4.13 million in Q1 2026 from $8.18 million in Q1 2025, aligning with the decrease in sales of goods.
• Research and development expenses increased by 56% to $5.43 million in Q1 2026 from $3.48 million in Q1 2025, largely due to preparations for the RELEASE study.
• Selling, general, and administrative expenses increased by 17% to $3.05 million in Q1 2026 from $2.60 million in Q1 2025.
• The company reported a significant swing from an operating loss of $4.15 million in Q1 2025 to an operating income of $21.15 million in Q1 2026.
• Net income for Q1 2026 was $18.32 million, a substantial improvement from a net loss of $3.62 million in Q1 2025.
• Basic earnings per share were $0.23 in Q1 2026, compared to a loss of $0.05 in Q1 2025. Diluted earnings per share were $0.22 in Q1 2026, compared to a loss of $0.05 in Q1 2025.
• Cash and cash equivalents and short-term bank deposits totaled $51.1 million as of March 31, 2026.
• Net cash provided by operating activities was $22.03 million in Q1 2026, a significant improvement from a use of $5.06 million in Q1 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant improvements in revenue, profitability, and cash flow, driven by key milestone achievements.

Positives

• Significant increase in total revenue to $33.75 million in Q1 2026 from $10.11 million in Q1 2025.
• Substantial growth in 'Revenues from License and R&D Services' to $26.33 million in Q1 2026, largely due to a $25.0 million milestone payment from Chiesi.
• Turnaround from an operating loss of $4.15 million in Q1 2025 to an operating income of $21.15 million in Q1 2026.
• Net income of $18.32 million in Q1 2026, a significant improvement from a net loss of $3.62 million in Q1 2025.
• Positive basic earnings per share of $0.23 and diluted earnings per share of $0.22 in Q1 2026.
• Strong positive cash flow from operations of $22.03 million in Q1 2026, compared to a negative cash flow of $5.06 million in Q1 2025.
• Elfabrio received approval for a 2 mg/kg every-four-weeks (E4W) dosage in the European Union in March 2026, leading to a milestone payment.
• Company believes its current cash and deposits are sufficient for at least 12 months of operations.

Negatives

• Revenues from selling goods decreased by 26% to $7.42 million in Q1 2026 compared to $9.99 million in Q1 2025, due to timing of orders from Pfizer and Fiocruz.
• Sales to Pfizer decreased by $5.53 million and sales to Fiocruz decreased by $0.56 million in Q1 2026 compared to Q1 2025.
• Research and development expenses increased by 56% to $5.43 million in Q1 2026, indicating higher investment in future development.
• The company continues to rely on external financing and collaboration payments, as revenues from product sales may not be sufficient to cover expenditures.
• The company has not generated significant revenues from Elelyso or Elfabrio sales to date, with current revenue drivers being milestone payments and R&D services.

Risks

• Risks related to the commercialization of Elfabrio, including market acceptance, competition, reimbursement, and regulatory actions, particularly the boxed warning.
• Potential failure or delay in clinical trials due to patient recruitment, safety issues, dosing, lack of effectiveness, or protocol adherence.
• Uncertainty in regulatory approval processes for other product candidates.
• Disruption of operations due to the regional conflict in the Middle East, impacting suppliers, partners, and clinical trial sites.
• Global economic conditions such as tariffs, trade restrictions, supply chain challenges, inflation, and banking instability.
• Risks associated with raising additional capital for future research and development.
• Challenges in managing relationships with collaborators and partners like Pfizer and Chiesi.
• Potential non-compliance by Fiocruz with purchase commitments under the Brazil Agreement.
• Dependence on third-party providers for services and supplies.
• Risks of patent infringement and challenges in enforcing intellectual property rights.
• Changes in healthcare laws and regulations.

Future Outlook

The company expects to continue incurring significant expenditures for research and development, particularly for the RELEASE study and other preclinical/clinical trials. Management believes current cash and deposits are sufficient for at least 12 months, but anticipates needing additional capital for future development. Future funding is expected from product sales, collaborations, licensing, and equity/debt offerings.

Management Comments

• The company is committed to leveraging its record of success as it develops treatments for rare and orphan diseases and continuously enhances its ProCellEx technology.
• Focus is shifting to new, early-stage product candidates for indications with high unmet needs, including renal diseases, addressing both genetic and non-genetic diseases.
• The company continuously evaluates potential strategic marketing partnerships and collaboration programs.
• The company believes its cash and cash equivalents and short-term bank deposits are sufficient to satisfy its capital needs for at least 12 months from the date this report is issued.
• The company may be required to raise additional capital to develop product candidates and continue research and development activities.

Industry Context

StockSavvy.ai notes that Protalix BioTherapeutics' Q1 2026 results reflect a significant shift in revenue drivers, moving from product sales to milestone payments and R&D services, a common pattern for biopharmaceutical companies advancing pipeline candidates. The increased R&D spending aligns with industry trends of investing heavily in innovation to address unmet medical needs in rare diseases.

Comparison to Industry Standards

• The significant revenue jump driven by a milestone payment is typical for biopharmaceutical companies that have achieved regulatory approvals or advanced pipeline candidates, such as those seen with companies like BioMarin Pharmaceutical or Vertex Pharmaceuticals upon successful drug launches or key regulatory milestones.
• The increase in R&D expenses as a percentage of revenue is consistent with early to mid-stage biopharmaceutical companies focused on pipeline development, where investment in clinical trials and research is prioritized over immediate profitability, contrasting with more mature pharmaceutical companies that may have a more balanced R&D to revenue ratio.
• The company's focus on rare diseases aligns with a growing segment of the pharmaceutical industry, where specialized treatments command premium pricing and address significant unmet needs, similar to strategies employed by companies like Alexion Pharmaceuticals (now AstraZeneca).

Legal Proceedings

• The company is not involved in any material legal proceedings.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance, net income, and earnings per share, alongside potential for future capital raises.
• Employees: Continued employment and potential for bonuses as per new employment agreement for Yaron Naos; increased R&D spending may lead to expanded roles.
• Customers: Continued supply of Elelyso and Elfabrio, with potential for new treatments in development.
• Suppliers: Potential for increased business due to higher R&D spending and manufacturing activities.
• Creditors: Improved financial health and cash flow may reduce perceived credit risk.

Next Steps

• Continue preparations for and initiation of the RELEASE study.
• Commence more advanced stages of preclinical and clinical trials for other product candidates.
• Continue to develop and enhance the ProCellEx technology.
• Focus on new, early-stage product candidates for indications with high unmet needs.
• Continuously evaluate potential strategic marketing partnerships and collaboration programs.
• Manage relationships with collaborators, distributors, and partners.

Key Dates

Recommendation

The Q1 2026 results demonstrate a significant turnaround with substantial revenue growth driven by milestone payments, a return to profitability, and positive operating cash flow. The company's strategic focus on rare diseases, coupled with advancements in its pipeline and technology, positions it for continued growth. While R&D expenses are increasing, this is a necessary investment for future product development. The availability of shares under the ATM program offers potential for further capital infusion to support these initiatives. The strong financial performance and positive outlook warrant a strong buy recommendation.

Keywords

Protalix BioTherapeutics, 10-Q, Q1 2026, Financial Results, Elfabrio, Elelyso, Fabry Disease, Gaucher Disease, Biopharmaceutical, Rare Diseases, Revenue, Net Income, R&D Expenses, Chiesi, Pfizer